AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein virilizer homolog

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q69YN4

UPID:

VIR_HUMAN

Alternative names:

-

Alternative UPACC:

Q69YN4; Q2M1N0; Q6AHX9; Q6NT78; Q7Z6C7; Q8IXH4; Q9BTH4; Q9H9C9; Q9NWR3; Q9P2B8; Q9UFW1

Background:

The Protein virilizer homolog is a crucial component of the WMM complex, involved in N6-methyladenosine (m6A) methylation of RNAs. This modification enhances mRNA splicing and RNA processing efficiency. It specifically promotes m6A methylation of mRNAs in the 3'-UTR near the stop codon, guiding m6A methylation at precise sites and playing a vital role in mRNA polyadenylation.

Therapeutic significance:

Understanding the role of Protein virilizer homolog could open doors to potential therapeutic strategies. Its pivotal function in RNA processing and modification underscores its potential as a target for therapeutic intervention, particularly in diseases where RNA splicing and processing are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.